Vaxcyte's shares surged 57% after its experimental pneumococcal vaccine VAX-31 showed immune responses comparable or superior to competitors in a late-stage Phase 3 trial. The vaccine met all primary endpoints, outperforming Pfizer's Prevnar 20 and Merck's Capvaxive on several strains, suggesting strong potential in the $3-6 billion adult pneumococcal vaccine market. The company reported no serious safety issues and plans to submit a US marketing application in early 2028, with more trial results expected in 2027. Analysts see significant upside potential for the stock as approval risks diminish.
Vaxcyte's shares surged on vaccine trial success. For readers following the health sector, here is Pluang's market snapshot as of Oct 05, 2026 22:02 WIB: Of 100 priced health-sector US stocks tradable on Pluang, 53 rose and 46 fell today. Notable movers include Bristol-Myers Squibb Co (BMY) at USD 58.54 with a -4.27% change, Charles River Laboratories Intl. Inc (CRL) at USD 302.05 with a +4.09% change, and Tilray Brands Inc (TLRY) at USD 3.75 with a +3.74% change.
BNP Paribas Exane raised NVIDIA's price target from $285 to $345 due to strong demand for its AI chips, signaling potential upside of about 45.6% from the current price. NVIDIA shares have gained about 25% in 2026, driven by growth in AI infrastructu...
Raymond James increased its price target for SBA Communications to $271 from $264, signaling a 68.6% upside from the current share price of $160.74. The growth is driven by rising mobile data demand, network expansions by wireless carriers, and stead...
SPX Technologies (NYSE: SPXC) recently traded near its 52-week low around $170, down about 1.6% from the previous close. Despite this, several analysts maintain positive outlooks with price targets ranging from $250 to $301, indicating potential upsi...
PBF Energy's shares have surged 173% over the past year, nearing record highs due to stronger refining margins and improved quarterly results. The company reduced its net term debt by over $1.4 billion in Q2 2026, refinanced notes, and maintained nea...
J D Wetherspoon reported an 8.6% increase in like-for-like sales in the first nine weeks of its new financial year, helped by favorable weather. However, profit before tax fell 28% to £58.60 million despite a 5.2% revenue rise to £2.24 billion, mainl...
